Pembrolizumab-Induced Immune-Mediated Glossitis

Pembrolizumab (Keytruda), an anti-PD-1 antibody used in the treatment of several different malignancies has been identified to cause adverse effects pertaining to multiple body systems which include respiratory, gastrointestinal, dermatologic, and endocrine manifestations known as immune-related adv...

Descripción completa

Detalles Bibliográficos
Autores principales: Alias, Alwin, Hall, James A, Kulkarni, Pruthali, Gowan, Alan C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Radiation Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8884081/
https://www.ncbi.nlm.nih.gov/pubmed/35242475
http://dx.doi.org/10.7759/cureus.21708

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8884081/
https://www.ncbi.nlm.nih.gov/pubmed/35242475
http://dx.doi.org/10.7759/cureus.21708

Ejemplares similares